Ozempic Cuts Depression Risk 44%: What the Study Shows

Semaglutide — the active ingredient in Ozempic and Wegovy — cut the risk of worsening depression by 44% and anxiety by 38% in a study of 95,490 people tracked over 13 years in Sweden. Published in The Lancet Psychiatry, the research also found a 47% drop in substance use disorders during treatment periods. The findings add growing evidence that the world's most talked-about weight-loss drug may be reshaping mental health treatment, not just waistlines.

Here's the part that should make you pause: two years ago, the FDA was investigating whether these same drugs caused suicidal thoughts. Now the largest study of its kind suggests they might do the opposite.

The Numbers Behind the Headline

Researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia followed people diagnosed with depression, anxiety, or both from 2009 to 2022 using Swedish national health registers. Of the 95,490 participants, 22,480 used GLP-1 medications.

The design was clever. Instead of comparing GLP-1 users to non-users (which introduces selection bias — healthier people might choose treatment), they compared the same individuals during periods when they were on the drugs versus periods when they weren't. Each person served as their own control.

During semaglutide use, psychiatric hospital visits and extended sick leave dropped by 42%. Depression risk fell 44%. Anxiety fell 38%. Substance use disorders — alcohol, drugs — fell 47%. Even suicidal behaviour decreased.

Not all GLP-1 drugs performed equally. Semaglutide showed the strongest effects. Liraglutide (Saxenda, Victoza) showed an 18% reduction. Exenatide and dulaglutide showed no mental health benefit at all. That specificity matters. If the effect were just "people who lose weight feel better," all the drugs should work. They don't.

The Brain Question Nobody's Answered

"The association was quite strong," said Markku Lähteenvuo from the University of Eastern Finland. He acknowledged the obvious possibilities: losing weight improves body image, better blood sugar control reduces fatigue and brain fog, drinking less alcohol (a known GLP-1 effect) naturally lifts mood.

But Lähteenvuo pointed to something else: "There may also be direct neurobiological mechanisms involved — for example, through changes in the functioning of the brain's reward system."

GLP-1 receptors don't just sit in the gut. They're scattered across the brain — in the hippocampus, the amygdala, the prefrontal cortex. These are the areas that regulate mood, fear, and decision-making. Animal studies have shown semaglutide reduces neuroinflammation, a process increasingly linked to depression in clinical research. The drug may be doing something in the brain that has nothing to do with weight loss.

Mark Taylor from Griffith University called the findings reassuring: "This was an independent study that should allay earlier fears of increased suicidality with GLP-1 receptor agonists."

Those fears were real. In 2023, the EU launched an investigation after reports of suicidal thoughts in Ozempic users. The FDA followed with its own probe. By January 2024, the agency's preliminary evaluation found no evidence of a link. By 2025, the FDA formally asked manufacturers to remove the suicidal behaviour warning from GLP-1 labels.

The trajectory — from suicide concern to antidepressant candidate — took less than three years.

A Billion People, $936 a Month

The WHO reported in September 2025 that more than 1 billion people worldwide live with mental health disorders. Depression and anxiety are the leading causes of disability globally. Existing antidepressants work for some, fail for others, and take weeks to show effects. A drug class that simultaneously addresses metabolic and psychiatric conditions would be genuinely transformative.

But there's a gap between what a drug can do and who can get it.

In the US, a month of Ozempic costs $936. In Sweden — where this study was conducted — it's roughly $90. In the UK and Australia, similar prices. The same drug, same molecule, different price tags depending on where you live.

India just cracked the door open. This month, Dr. Reddy's Laboratories, Glenmark, Zydus, and Sun Pharma all launched generic semaglutide. The cheapest options start at about 1,290 rupees per month — around $15. Dr. Reddy's version runs about $50 monthly. They're planning to expand to Canada, Turkey, and Brazil this year.

Researchers from a March 2026 study published in STAT News estimated that generic semaglutide could be mass-produced for about $3 per person per month. Three dollars. For a drug that might treat diabetes, obesity, depression, anxiety, and addiction simultaneously.

About 27% of adults worldwide meet the clinical criteria for GLP-1 treatment. Most of them live in low- and middle-income countries where access to these drugs is, right now, close to zero.

What This Study Doesn't Prove

This was observational, not a randomised controlled trial. The researchers tracked real-world use patterns, not placebo-controlled groups. That means confounders lurk everywhere. People who stay on semaglutide might be more engaged with their health generally. The periods when they stopped might have coincided with life disruptions that worsened their mental health independently.

The within-individual design reduces some of this noise, but it doesn't eliminate it. Taylor acknowledged as much: "These are associations where causality is not proven. So, a randomised controlled trial testing this dual efficacy is warranted."

There's also the question of what happens when people stop. Gabriel Iglesias recently described gaining back 20 pounds "immediately" after quitting Ozempic. If the mental health benefits of GLP-1 drugs track the metabolic ones, they may require lifelong use — which circles back to the access and cost problem.

And there's a darker edge. Telehealth platforms now prescribe GLP-1 drugs with minimal screening. For people with eating disorders, a drug that suppresses appetite and alters the brain's reward circuitry could reinforce disordered behaviour rather than treat it. The mental health benefits found in this study came from people diagnosed with depression and anxiety, not people using the drug primarily for cosmetic weight loss.

The $48 Billion Question

Novo Nordisk's revenue hit $48.6 billion in 2025, driven largely by semaglutide products. Ozempic alone has generated $63 billion in global sales over the past five years. Every new indication — heart disease, kidney protection, now mental health — expands the potential market by hundreds of millions of people.

The company is fighting generic competition in Indian courts right now, suing Dr. Reddy's over brand name similarities. The tension is structural: the same drug that could help a billion people with mental health conditions sits behind patent walls and pricing structures that keep it from most of them.

Sweden, where this study was conducted, has universal healthcare. Everyone in the study had access to GLP-1 drugs through the national health system. That's not the reality for the 280 million people living with depression in countries where a month of treatment costs more than a month of rent.

What Happens Next

Clinical trials specifically testing semaglutide for depression and anxiety will likely follow this study. If those trials confirm the observational findings, regulatory agencies will face a decision: approve GLP-1 drugs for psychiatric indications, or leave doctors to prescribe off-label.

Either way, the ground has shifted. A drug designed to mimic a gut hormone has wandered into the territory of antidepressants, anti-addiction medications, and possibly neuroprotective agents. The science is moving faster than the systems built to evaluate, price, and distribute it.

The question isn't whether semaglutide affects the brain. The GLP-1 receptors sitting in your hippocampus answer that. The question is whether a drug that costs $3 to make will cost $936 to buy in the places that need it most.